An interventional study of CBD vape liquid and Placebo Liquid in Cannabis Use Disorder, sponsored by University Hospital, Bordeaux. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Treatment
The purpose of this trial is to evaluate the effectiveness of a 70mg/ml CBD e-liquid used in an e-cigarette, in reducing or stopping cannabis use at the 12-week follow-up, compared to a placebo liquid.
There is currently no treatment for cannabis use disorder, which is the most widely used illicit substance in the world. Preclinical studies have shown that CBD may be beneficial in treating addiction. A pilot study evaluating CBD delivered via e-cigarette showed encouraging results in reducing cannabis use (and the use of tobacco consumed alongside cannabis).
This study will compare a group that will use a CBD vape liquid at 70 mg/ml with a choice of two flavors (cannabis or red berries) to a group that will use a placebo vape liquid with a choice of two flavors (cannabis or red berries).
Eligible patients will be randomized into one of the two groups and will be required to use their e-liquid for 12 weeks. Weekly follow-up is scheduled, alternating between in-person visits and phone calls every other week. Patients will also have access to a nicotine-containing e-liquid in an additional tank to address co-addiction to tobacco.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals aged 18 or older
A person with an unstable psychiatric condition (as determined by a psychiatric evaluation conducted by the addiction specialist during the initial consultation),
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The control group will use a placebo vape liquid with a choice of two flavors (cannabis or red berries)
Drug: Placebo Liquid
The intervention group will use a CBD vape liquid at 70 mg/ml with a choice of two flavors (cannabis or red berries)
Drug: CBD vape liquid
70 mg/ml CBD vape liquid available in two flavors (cannabis or red berries)
The comparator product will be a placebo liquid available in a choice of 2 flavors (cannabis or red fruits), identical to those used for the experimental group.
Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 12 weeks
Proportion of patients for whom the intervention was successful, defined as a reduction of at least 50% in the total reported amount of cannabis consumed (in grams) at the end of the 12-week follow-up period, compared to baseline.
Time frame: From baseline to 12 weeks
Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 6 months
Proportion of patients who responded to the intervention, defined as a reduction of at least 50% in the reported amount of cannabis consumed in grams at 6 months compared to baseline
Time frame: From baseline to 6 months
Total amount of cannabis consumed
Total amount of cannabis consumed in grams at the end of the 12-week follow-up period
Time frame: At 12 weeks
Number of days of cannabis abstinence - 12 weeks
Number of days of cannabis abstinence at the end of the 12-week period
Time frame: From baseline to 12 weeks
Number of days of cannabis abstinence - 6 months
Number of days of cannabis abstinence at 6 months
Time frame: From baseline to 6 months
Self-reported number of joints smoked - 12 weeks
Self-reported number of joints smoked per day at 12 weeks
Time frame: From baseline to 12 weeks
Self-reported number of joints smoked - 6 months
Self-reported number of joints smoked per day at 6 months
Time frame: From baseline to 6 months
Self-reported budget spent in euros to purchase cannabis - 12 weeks
Self-reported budget spent in euros to purchase cannabis at the end of the 12 weeks
Time frame: From baseline to 12 weeks
Self-reported budget spent in euros to purchase cannabis - 6 months
Self-reported budget spent in euros to purchase cannabis at 6 months
Time frame: From baseline to 6 months
Self-reported number of cigarettes smoked - 12 weeks
Self-reported number of cigarettes smoked per day at 12 weeks
Time frame: From baseline to 12 weeks
Self-reported number of cigarettes smoked - 6 months
Self-reported number of cigarettes smoked per day at 6 months
Time frame: From baseline to 6 months
Exhaled carbon monoxide
Exhaled carbon monoxide measured in parts per million (ppm) of CO per unit of air using an exhaled carbon monoxide tester at 12 weeks
Time frame: At 12 weeks
Self-reported consumption of psychoactive substances - 12 weeks
Self-reported consumption of psychoactive substances in units or grams per week (alcohol, cocaine, ketamine, new synthetic drugs, heroin, other opioids, etc.) at 12 weeks
Time frame: At 12 weeks
Self-reported consumption of psychoactive substances - 6 months
Self-reported consumption of psychoactive substances in units or grams per week (alcohol, cocaine, ketamine, new synthetic drugs, heroin, other opioids, etc.) at 6 months
Time frame: At 6 months
Cannabis Withdrawal
Cannabis Withdrawal Scale score at 12 weeks It is a 19-item questionnaire assessing cannabis withdrawal symptoms and their impact on daily activities. Each of the 19 items is rated on a scale from 0 to 10. Two separate scores are calculated: Personal experience (withdrawal intensity) (min 0; max 190) and Negative impact on daily activities (min 0 max 190) Higher scores indicate more severe cannabis withdrawal symptoms. Higher negative-impact scores indicate greater interference with daily activities. A decrease in either score indicates improvement. An increase in either score indicates worsening.
Time frame: At 12 weeks
Use of symptomatic treatments
Use of symptomatic treatments for withdrawal symptoms during the 12-week follow-up
Time frame: From baseline to 12 weeks
Cannabis cravings at 12 weeks
Visual Analog Scale for cannabis cravings at 12 weeks It is used to measure the intensity of an individual's craving or urge to use cannabis. Score range (min: 0 max: 100-mm or min=0 max:10 Interpretation: 0: No craving at all; 100 mm (or 10): Extremely intense craving. A decrease in score indicates reduced cannabis craving (improvement).
Time frame: At 12 weeks
Cannabis cravings at 6 months
Visual Analog Scale for cannabis cravings at 6 months It is used to measure the intensity of an individual's craving or urge to use cannabis. Score range (min: 0 max: 100-mm or min=0 max:10 Interpretation: 0: No craving at all; 100 mm (or 10): Extremely intense craving. A decrease in score indicates reduced cannabis craving (improvement).
Time frame: At 6 months
Anxiety and Depression at 12 weeks
Hospital Anxiety and Depression scale at 12 weeks Sef-reported questionnaire. It consists of 14 items, divided into two subscales: Anxiety: (min 0 and max 21); Depression (min 0 and max 21)) For each subscale (anxiety and depression): Score: 0-7 (Normal); 8-10 (Borderline / possible symptoms); 11-21 (Abnormal / clinically significant symptoms). Higher scores = worse outcome The anxiety and depression subscales are generally reported and analysed separately. The total score (0-42) can also be used as a measure of overall psychological distress.
Time frame: At 12 weeks
Anxiety and Depression at 6 months
Hospital Anxiety and Depression scale at 6 months Sef-reported questionnaire. It consists of 14 items, divided into two subscales: Anxiety: (min 0 and max 21); Depression (min 0 and max 21)) For each subscale (anxiety and depression): Score: 0-7 (Normal); 8-10 (Borderline / possible symptoms); 11-21 (Abnormal / clinically significant symptoms). Higher scores = worse outcome The anxiety and depression subscales are generally reported and analysed separately. The total score (0-42) can also be used as a measure of overall psychological distress.
Time frame: At 6 months
Quality of Life - Baseline
World Health Organization Quality of Life scale at baseline Regarding the commonly used scale(26 items): Domain scores (transformed 0-100) (min=0; max 100); or Domain scores (transformed 4-20)(min=4; max=20); The four domains are: Physical health; Psychological health; Social relationships; Environment Interpretation: Higher scores indicate better quality of life, while lower scores indicate poorer quality of life.
Time frame: At baseline
Quality of Life - 12 weeks
World Health Organization Quality of Life scale at 12 weeks Regarding the commonly used scale (26 items): Domain scores (transformed 0-100) (min=0; max 100); or Domain scores (transformed 4-20)(min=4; max=20); The four domains are: Physical health; Psychological health; Social relationships; Environment Interpretation: Higher scores indicate better quality of life, while lower scores indicate poorer quality of life.
Time frame: At 12 weeks
Quality of Life - 6 months
World Health Organization Quality of Life scale at 6 months. Regarding the commonly used scale (26 items): Domain scores (transformed 0-100) (min=0; max 100); or Domain scores (transformed 4-20)(min=4; max=20); The four domains are: Physical health; Psychological health; Social relationships; Environment Interpretation: Higher scores indicate better quality of life, while lower scores indicate poorer quality of life.
Time frame: At 6 months
Average reported amount of CBD or placebo vape liquid
Average reported amount of CBD or placebo vape liquid in milliliters per week during the 12-week follow-up period
Time frame: From baseline to 12 weeks
Reported amount of CBD vape liquid
Reported amount of CBD vape liquid in milliliters during the 7 days prior to the 6-month visit, including the concentration of the liquid consumed (in mg/ml)
Time frame: During the 7 days prior to the 6-month visit
Number of adverse effects attributed to CBD
Adverse effects attributed to CBD during the 12-week follow-up period
Time frame: From baseline to 12 weeks
Insomnia at 12 weeks
Insomnia Severity Index at 12 weeks. The Insomnia Severity Index (ISI) is a self-report questionnaire used to assess the severity of insomnia symptoms: Minimum score: 0, Maximum score: 28. Interpretation: Higher scores indicate worse insomnia severity (a poorer outcome). The questionnaire contains 7 items, each scored from 0 to 4.
Time frame: At 12 weeks
Insomnia at 6 months
Insomnia Severity Index at 6 months The Insomnia Severity Index (ISI) is a self-report questionnaire used to assess the severity of insomnia symptoms: Minimum score: 0, Maximum score: 28. Interpretation: Higher scores indicate worse insomnia severity (a poorer outcome). The questionnaire contains 7 items, each scored from 0 to 4.
Time frame: At 6 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →